AirSculpt Technologies, a leader in premium body contouring, will announce its third quarter fiscal 2026 financial results before market open on November 6, 2026. The company will hold a conference call at 8:30 a.m. Eastern Time the same day to discuss the results, accessible via phone or webcast. This update is important for investors tracking AirSculpt's performance in the growing cosmetic procedure market. A replay of the webcast will be available for 90 days for those unable to attend live.
AirSculpt Technologies' upcoming third quarter fiscal 2026 earnings announcement provides context for readers interested in health sector trends. For readers following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: Of 150 priced health-sector US stocks tradable on Pluang, 48 rose and 100 fell today. Regeneron Pharmaceuticals Inc (REGN) rose 13.27% to USD 927.38 with Pluang order activity showing 80% Sell and 20% Buy, typical hold time 108 days. Ginkgo Bioworks Holdings Inc (DNA) fell 12.60% to USD 9.81 with 44% Sell and 56% Buy, typical hold time 9 days. Twist Bioscience Corp (TWST) dropped 12.36% to USD 152.02 with 18% Sell and 82% Buy, typical hold time 27 days.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NVIDIA has published detailed implementation recipes for its Cosmos world models, enabling developers to create simulations for vehicles, robots, and surgical procedures. These recipes guide model adaptation, testing, and GPU deployment, supporting v...
